Q3 2026 Humana Inc. Earnings Conference Call - HUMANA INC

Explicit Guidance:

• Full-Year 2026 Adjusted EPS: Increased to at least $9.50 (up from previous "at least $9" guidance), reflecting better-than-expected cost trends for new and existing members.
• Long-Term Margin Target: Portfolio positioned to deliver margin progression in 2027 to achieve a 3%+ pre-tax margin by 2028.
• 2027 Membership: Anticipated to be up for 2027, driven by AEP performance ahead of expectations, though specific growth rate is not quantified.
• 2027 Cost Trend: Expected to rise to 8–9% (up from 7–8% in 2026), driven by a 14–15% increase in Part D trends due to the health technology pipeline; medical costs expected to be slightly higher.
• 2028 Margin Outlook: Anticipation of a one-time tailwind in 2028 resulting from BY28 Star ratings exceeding top-quartile goals; specific financial split between reinvestment and shareholder return (dividends/buybacks) to be quantified later in 2027 or Q4 2027.
• 2028 Capital Allocation: Option to purchase clinics from the BlackRock JV beginning in 2028; if clinics are not acquired by end of 2033, BlackRock has a right to purchase remaining clinics.

Business-Segment Outlook:

• Medicare Advantage (MA):
  • 2028 Strategy: Management plans to build cost and benefit structures to sustain operations at a top-quartile Star rating (approx. 4.17 member-weighted for BY28), viewing this as the sustainable baseline rather than top-decile performance.
  • 2027 Margin: Expecting material improvement in MA margins (both stars-adjusted and unadjusted) moving into profitability, even reflecting the 2026 Star rating headwind, driven by pricing optimization and operational transformation.
  • Group MA: Significant margin recovery expected post-2028, following a 500 basis point improvement in contracting from the prior year; full benefit realization tied to the return of Star bonus payments in 2028.
  • 2029 Star Ratings: Projected to achieve top-quartile performance for Benefit Year 2029 (BY29).
• CenterWell (PCO):
  • Membership Growth: Added ~147,000 members (30% growth) in 2026; expects continued expansion of the PCO footprint as a priority for future organic growth and M&A.
  • Cost Pressure: Identified pressure in one specific geography/patient group; expects to mitigate most of this impact in 2027 through aggressive network management, benefit design changes by payers, and contracting improvements.
• Medicaid:
  • Footprint: Expanded to 13 states (11 active); pending implementations in Georgia and Texas.
  • Growth: Membership grew by 104,000 in 2026; continued focus on integrated dual-SNP plans (HEID and FIDI) and dual eligibles.

Market and Competitive Outlook:

• Competitive Dynamics: Expecting less membership growth in 2027 compared to 2026 due to fewer new members entering (lower marketing/onboarding headwinds).
• Market Structure: Anticipating consolidation among smaller plans, creating tailwinds for larger players like Humana; outperformance attributed to improved distribution partner quality and relationships.
• Pricing Strategy: 2027 pricing prioritized for margin over volume; product positioning largely aligned with bid expectations, with focus on simple, affordable, and predictable coverage.
• Reinsurance: Reinsurance usage to fund subsidiaries has reduced capital requirements (from ~12% to ~10% of premiums); no substantial change in reinsurance strategy expected through 2027.

Macro / Industry Outlook:

• Cost Trends: Health technology pipeline driving increased Part D spend (14–15%) and slightly higher medical costs (8–9% overall trend) in 2027.
• Regulatory Environment: No known incremental regulatory headwinds entering 2027; focus remains on navigating J-curves for Medicaid and PCO.
• Economic Environment: Management cites a need for operational discipline to navigate potential external volatility, emphasizing the ability to sustain debt-to-cap efficiency despite business cycle fluctuations.

Strategic Initiatives:

• BlackRock Joint Venture: Closed new JV replacing the Welsh Carson JV; expected to reduce cost of capital by approximately 130 basis points in debt-to-cap ratio (Q4 impact); BlackRock holds exit rights and purchase options.
• Divestment: Completed divestment of minority interest in Gentiva, generating ~$900 million in pre-tax proceeds.
• Capital Optimization:
  • Dividends: Plan to grow dividends to normalized payout levels as earnings power recovers; current buybacks primarily offset dilution.
  • Buybacks: No immediate plan for aggressive buybacks due to debt-to-cap constraints; expects increased repurchases once balance sheet flexibility allows.
  • Investment Priority: Capital deployment focused on Medicaid and CenterWell (organic + M&A); no separate targets for M&A vs. organic, evaluated on return on capital.
• Operational Transformation: Multi-year efficiency program progressing; detailed update scheduled for a December investor event.
• Acquisition: Acquisition of MaxHealth (completed Q1 2026) contributing to CenterWell growth; future PCO expansion prioritized.

Risks and Headwinds to Outlook:

• Star Rating Volatility: Competitive actions by peers may narrow the gap between Humana and top-quartile targets over the next 15 months, potentially reducing the size of the 2028 one-time tailwind.
• Unquantifiable Tailwind: The final amount of 2028 Star-related excess earnings (to be split between reinvestment and shareholders) cannot be precisely quantified until late 2027 due to membership mix, competitive dynamics, and operational capacity constraints.
• 2027 Membership Uncertainty: Retention rates for 2027 remain unknown at this stage, preventing specific growth rate guidance beyond the "up" direction.
• PCO Specifics: Continued pressure in specific Florida facilities and payer networks requires ongoing monitoring, though mitigation actions are in place.

Management Tone on the Future:

• Confidence Level: High confidence; management states they are "ahead of plan" and "on a positive trajectory" with "momentum."
• Discipline Over Conservatism: Repeated emphasis on "operational discipline" rather than conservatism; willing to take calculated risks to improve outcomes but managing cost structures to ensure long-term viability at top-quartile benchmarks.
• Forward-Looking Sentiment: Describes the current position as "good," with "tangible results" of strategy becoming visible; expresses pride in the team's ability to navigate headwinds and deliver value.

Miscellaneous:

• Investor Update: Scheduled for December 10th to provide detailed updates on 2028 commitments, the 2028 Star tailwind breakdown, and progress on the 2028 3% margin target.
• Value-Based Care: Maintaining focus on aligning members with high-quality providers; no significant change expected in the percentage of value-based care, though infrastructure and governance are being strengthened.
• Capital Efficiency: The new BlackRock JV structure removes the need to fund a put option in 2027, avoiding a potential 130 basis point increase in debt-to-cap ratio.